Risankizumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Risankizumab: From Psoriasis to Dermatitis
One-Sentence Summary
Risankizumab is a humanised IgG monoclonal antibody targeting the p19 subunit of IL-23, first approved in Japan (2019) for psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis. The TxGNN model predicts it may be effective for Dermatitis (including atopic dermatitis), with 7 clinical trials and 17 publications currently supporting this direction. Evidence includes a completed placebo-controlled Phase 2 RCT specifically in moderate-to-severe atopic dermatitis, though the drug is not currently marketed in Finland and key safety labeling data is missing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Psoriasis (psoriasis vulgaris, psoriatic arthritis, generalized pustular/erythrodermic psoriasis — per first global approval; no Finland license record available) |
| Predicted New Indication | Dermatitis |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L2 |
| Finland Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed original MOA data for risankizumab is flagged as a data gap in this evidence pack. However, the pack's own literature and repurposing rationale supply the mechanistic picture: risankizumab is an anti-IL-23 (p19 subunit) monoclonal antibody that blocks the IL-23/Th17 signaling axis (PMID 31098898). This pathway is a well-established driver of keratinocyte hyperproliferation and inflammation in psoriasis, its original indication.
The IL-23/Th17 axis also contributes to other chronic inflammatory skin diseases, including atopic dermatitis, where Th2, Th22 and — increasingly recognized — Th17 pathways overlap. This shared immunopathogenesis is the biological basis for the TxGNN prediction linking risankizumab to dermatitis.
Consistent with this rationale, a dedicated Phase 2 placebo-controlled RCT (NCT03706040) directly tested risankizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis, and a real-world cohort has reported combined dupilumab + risankizumab use in patients with concomitant atopic dermatitis and psoriasis. Notably, the literature also documents a recognized paradoxical adverse effect — eczematous/dermatitis-like eruptions emerging during risankizumab treatment for psoriasis (e.g., PMID 33185530, 36939506, 41645692) — which is a double-edged signal: it confirms cutaneous immunologic activity relevant to dermatitis pathways, but also flags a safety consideration that should be weighed alongside efficacy.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03706040 | Phase 2 | Completed | 172 | Randomized, placebo-controlled, double-blind study of risankizumab in adult and adolescent subjects with moderate to severe atopic dermatitis — the most directly relevant trial for this indication |
| NCT04908475 | Phase 4 | Completed | 352 | Open-label comparison of risankizumab vs. apremilast in moderate plaque psoriasis; supports mature clinical use in inflammatory skin disease |
| NCT05969223 | Phase 4 | Completed | 214 | Double-blind study of risankizumab in moderate-to-severe genital or scalp psoriasis |
| NCT04818385 | N/A (observational) | Completed | 240 | Taiwan prospective cohort on durability of risankizumab response (PASI 90) vs. other biologics in moderate-to-severe plaque psoriasis |
| NCT07021495 | N/A (observational) | Recruiting | 840 | Real-world biomarker profiling study covering atopic dermatitis, psoriasis and other immune-mediated inflammatory skin diseases |
| NCT07041112 | N/A (observational) | Completed | 1000 | Pharmacogenetic study on 10-year survival of biologic therapies in cutaneous psoriasis ± psoriatic arthritis |
| NCT07352566 | Phase 4 | Not yet recruiting | 10 | Microdevice-based topical drug testing platform for atopic dermatitis and psoriasis; low direct relevance |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36588137 | 2023 | RCT | Dermatology and Therapy | Phase 2 randomized, double-blind, placebo-controlled trial of risankizumab in moderate-to-severe atopic dermatitis, supporting IL-23/IL-22 blockade rationale in AD |
| 31098898 | 2019 | Review | Drugs | "First Global Approval" review: risankizumab's MOA (anti-IL-23 p19) and initial approval history in psoriasis-spectrum disease |
| 39201826 | 2024 | Review | Children (Basel) | Narrative review of biologics/small molecules for pediatric alopecia areata, psoriasis, atopic dermatitis and hidradenitis suppurativa |
| 33078990 | 2020 | Review | Expert Opinion on Biological Therapy | Review of current and emerging biologics for pediatric atopic dermatitis |
| 40856907 | 2025 | Review | American Journal of Clinical Dermatology | Systematic review of systemic therapies (including risankizumab) for erythrodermic psoriasis |
| 40794374 | 2025 | Review | Inflammopharmacology | Systematic review of interleukin inhibitors (incl. IL-23) in lichen planus, therapeutic and paradoxical cutaneous effects |
| 39668419 | 2025 | Cohort | International Journal of Dermatology | Effectiveness and safety of combined dupilumab and risankizumab in patients with concomitant atopic dermatitis and psoriasis |
| 40071317 | 2025 | Cohort | Experimental Dermatology | Retrospective longitudinal study of risankizumab treatment response in patients with a history of erythrodermic psoriasis |
| 38607726 | 2024 | Review | Military Medicine | Reappraisal of systemic immunomodulators, including risankizumab, for psoriasis and eczema in military populations |
| 37381703 | 2023 | Case Report | Journal of Dermatological Treatment | Case of acrodermatitis continua of Hallopeau successfully and rapidly treated with risankizumab |
Finland Market Information
No marketing authorizations for risankizumab are currently recorded in Finland (market status: Not Marketed, 0 authorizations).
Safety Considerations
Please refer to the package insert for safety information.
Note: Retrieval of the TFDA/EMA package insert (warnings, contraindications) is flagged as a Blocking data gap in this evidence pack, meaning a formal S1 safety pre-assessment cannot currently be completed. Separately, the literature evidence base surfaces a recurring paradoxical adverse-event signal — eczematous/dermatitis-like eruptions during risankizumab treatment (PMID 33185530, 36939506, 33185535, 41645692, 37014149) — that should be factored into any future safety review for a dermatitis indication specifically.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic rationale (IL-23/Th17 blockade) and a completed Phase 2 RCT in atopic dermatitis (L2 evidence) provide a genuine efficacy signal, but a Blocking data gap on official safety labeling and the drug's absence from the Finnish market (0 authorizations) mean the safety pre-assessment (S1) cannot be completed at this time.
To proceed, the following is needed:
- TFDA/EMA-equivalent package insert (warnings and contraindications) to complete S1 safety pre-assessment
- Confirmed original indication and full MOA documentation from DrugBank
- DDI dataset (current query returned no results)
- Targeted review of the paradoxical eczematous-reaction literature to assess risk when repurposing toward a primary dermatitis indication
- Regulatory pathway assessment for Finland market entry given current "Not Marketed" status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.